StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Emgality (galcanezumab) by Quarter

Emgality (galcanezumab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)

QuarterlyAnnual

Eli Lilly Emgality (galcanezumab): $250M in Q4 2024, up 34.2% from a year earlier. That is the highest of the 27 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2024
250
Period ended Dec 31, 2024
Change on a year earlier
+34.2%
186 in Q4 2023
History
27 quarters
Since Q1 2018
Sources
23
Documents cited below

Where the Q4 2024 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K FY2024 (filed 2025-02-19) ↗

Reported in Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEmgality (galcanezumab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)Year on yearSource
Q4 2024Dec 31, 2024250+34.2%Form 10-K FY2024 (filed 2025-02-19) ↗
Q3 2024Sep 30, 2024203+20.4%Form 10-Q (filed 2024-10-30) ↗
Q2 2024Jun 30, 2024192+13.4%Form 10-Q (filed 2024-08-08) ↗
Q1 2024Mar 31, 2024226+46.3%Form 10-Q (filed 2024-04-30) ↗
Q4 2023Dec 31, 2023186+6.0%Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗
Q3 2023Sep 30, 20231690.0%Form 10-Q (filed 2024-10-30) ↗
Q2 2023Jun 30, 2023169+7.5%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023154+3.3%Form 10-Q (filed 2024-04-30) ↗
Q4 2022Dec 31, 2022176+8.7%Earnings Release (Form 8-K FY2022Q4 EX-99.1) (filed 2023-02-02) ↗
Q3 2022Sep 30, 2022169+20.4%Form 10-Q (filed 2023-11-02) ↗
Q2 2022Jun 30, 2022158+0.8%Form 10-Q (filed 2023-08-08) ↗
Q1 2022Mar 31, 2022149+24.9%Form 10-Q (filed 2023-04-27) ↗
Q4 2021Dec 31, 2021162+47.0%Earnings Release (Form 8-K FY2021Q4 EX-99.1) (filed 2022-02-03) ↗
Q3 2021Sep 30, 2021140+53.0%Form 10-Q (filed 2022-11-01) ↗
Q2 2021Jun 30, 2021156+78.8%Form 10-Q (filed 2022-08-04) ↗
Q1 2021Mar 31, 2021120+61.5%Form 10-Q (filed 2022-04-29) ↗

Breakdown

What makes up emgality (galcanezumab)

Cite this data

StockData. (2026). Eli Lilly Emgality (galcanezumab) ($M), quarterly Q1 2018–Q4 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-emgality-ww

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.